Emma Stone – Emma Stone Plans To Study Biology

Emma Stone's onscreen romance with Spider-man has inspired the actress to study biology.

The Help star, who plays Peter Parker's first love Gwen Stacy in the film, visited a laboratory for the first time on the set and was left fascinated by the work of real scientists - and now wants to become one.

But first she has to exchange film scripts for biology books.

She tells WENN, "It was the first (time) I'd ever been angry about not going to college because I was fascinated by what they were showing us (at the laboratory). I thought, 'What do I need to do to intern?' You need to be a college graduate!

"It sucks because I can learn, I swear... I got so interested in biology, learning about medicine and regeneration and stem cells. It expanded my mind in so many ways, so now I'm gonna go take a biology class. What's amazing is you can do it at home."

And Stone has a couple of great minds on tap if her studies get too tough: "My aunt and uncle were scientists that worked for Merck and they had a hand in creating the cervical cancer vaccine and Gardasil, so they are incredibly intelligent and fantastic minds. I'd always been fascinated by what they did."

See more here:
Emma Stone - Emma Stone Plans To Study Biology

Emma Stone plans to study biology

The Help star, who plays Peter Parker's first love Gwen Stacy in the film, visited a laboratory for the first time on the set and was left fascinated by the work of real scientists - and now wants to become one.

But first she has to exchange film scripts for biology books.

She tells WENN, "It was the first (time) I'd ever been angry about not going to college because I was fascinated by what they were showing us (at the laboratory). I thought, 'What do I need to do to intern?' You need to be a college graduate!

"It sucks because I can learn, I swear... I got so interested in biology, learning about medicine and regeneration and stem cells. It expanded my mind in so many ways, so now I'm gonna go take a biology class. What's amazing is you can do it at home."

And Stone has a couple of great minds on tap if her studies get too tough: "My aunt and uncle were scientists that worked for Merck and they had a hand in creating the cervical cancer vaccine and Gardasil, so they are incredibly intelligent and fantastic minds. I'd always been fascinated by what they did."

More here:
Emma Stone plans to study biology

MU biochemistry assistant professor Peter Cornish named Pew Scholar

Friday, June 15, 2012 | 7:45 p.m. CDT

COLUMBIA Peter Cornish has always been interested in discovery and figuring out how things function.

These interests have led him to national recognition.

Cornish, a biochemistry assistant professor at MU, is one of the22individuals in the nation to be named a 2012 Pew Scholar in the biomedical sciences.He is the first MU faculty member to receive the honor while working at the university.

It is a big deal for me and a big deal for the university, Cornish said. It not only provides money for research but also notoriety.

Pew Scholars are considered to be among the most innovative young researchers. According to the Pew Charitable Trusts website, the community includes Nobel Prize winners, MacArthur Fellows and Albert Lasker BasicMedical Research Award recipients.

Since 1985, the program has invited top research institutions to nominate one candidate each year. It received 134 eligible nominations from a pool of 179 institutions this year.

Winners receive $240,000over four years to help them pursue their research without major restrictions.The program looks to back scientists early in their careers so they can take calculated risks to help advance the human health field.

Even though Cornish only started at MU in the spring of 2010, his talent, past work and future potential made him a great fit to be MUs Pew Scholar nominee, said Gerald Hazelbauer, chairman of the Biochemistry Department.

Cornish is working with technologycalled Frster resonance energy transfer (FRET), which is relatively new and developing quite rapidly, Hazelbauer said. Single-molecule FRET gives scientists the ability to look at molecules on an individual basis.

Visit link:
MU biochemistry assistant professor Peter Cornish named Pew Scholar

Clemson dean named president at Presbyterian College

Published: Saturday, June 16, 2012 at 3:15 a.m. Last Modified: Friday, June 15, 2012 at 10:18 p.m.

A Clemson University dean was announced as the next president of Presbyterian College Friday.

The colleges board of trustees elected Claude C. Lilly, Clemsons dean of the College of Business and Behavioral Science, to serve as Presbyterian Colleges 17th president. He will succeed John Griffith, Presbyterian Colleges president since 1998.

I am honored by the opportunity to serve as the new president of Presbyterian College and look forward to building on the outstanding foundation laid by faculty members, trustees, staff, students and alumni under the leadership of President Griffith, Lilly stated in a news release posted to the PC website Friday morning. My wife, Fran, and I are eager to become a part of the Clinton community and a PC environment that inspires learning.

Lilys career spans higher education and private industry and includes 39 years of administrative and teaching experience at Texas Tech University, the University of Southern California, Florida State University and the Belk College of Business Administration at the University of North Carolina. The Georgia native has served in his current capacity with Clemson since 2007, during which he played a critical role in relocating the MBA, the MBA in Entrepreneurship, the MACC and the MS programs to downtown Greenville.

Dr. Lilly has an impressive record of leadership in both the academic and private sectors and truly embodies the PC motto of Dum Vivimus Servimus While We Live, We Serve, said William B. Shearer, Jr., chairman of the Presbyterian College Board of Trustees. With a compelling vision for academic program development and community and financial growth, he will be a dynamic, creative, and decisive leader committed to a strong future for Presbyterian College.

The Lillys have four children and seven grandchildren.

Lilly will assume his new role on July 15.

Read this article:
Clemson dean named president at Presbyterian College

Study: Omega-3 effecting brain health a myth

Study: Omega-3 helping brain health a myth

Omega -3 Fatty Acids effect on brain health in people 60 or older may be more myth than medical fact.

Researchers with the London School of Hygiene and Tropical Medicine issued a report Wednesday that found direct evidence on the effect of omega-3 on incident dementia is lacking.

Dr. Alan Dangour, author of the new study, admits he was disappointed in the results which reviewed 3,536 patients taking placebos versus fish oil for six months to more than three years.

"This is a great shame, Dangour said. "It would be lovely to find a solution for cognitive decline and dementia, and unfortunately, the evidence as it stands says it does not benefit cognitive function in older people."

Dr. Deborah Harding, CEO of The Harding Anti-Aging Center in Orlando, says the window of time for the studies is too short to make any real conclusions.

"This study, in my opinion, doesnt tell us anything," she said. "Number one, its too short, number two they are not measuring the Omega fish oil levels in the participants blood."

Hardings patients are given levels of Omega-3 based on their individual blood results. That was never done in any of the clinical studies reviewed in the London report. Dementia is a progressive illness which mainly affects older people. The changes are subtle at first, then over time, the decline in memory and verbal fluency is stunted.

According to the study, "previous research from observational studies has suggested that increased consumption of fish oils rich in omega-3 long-chain polyunsaturated fatty acids (omega-3 PUFA) may reduce the chance of developing dementia, while other studies show no effect."

Dr. Dangour, a nutritionist and co-author of the study concedes time may play a key in the impact of fish oil on the brains health.

Go here to see the original:
Study: Omega-3 effecting brain health a myth

Eastman Kodak files for auction of Digital Imaging patents

 

Kodak(Reuters) - Eastman Kodak Co filed a motion on Monday seeking approval of bidding procedures for bankruptcy auction of its Digital Capture and Kodak imaging Systems and Services patent portfolios, which together comprise more than 1,100 patents.

Kodak's motion outlines a sale process such that only the winning bidder and the successful bid amount will be publicly announced at the end of the auction, it said in a statement.

Kodak, now in bankruptcy, expects the motion to be heard by the Court on July 2, with the auction being held in early August and the winning bidder being announced by August 13.

"In filing these proposed procedures in advance of the June 30 deadline in our lending agreement, we are moving ahead as quickly as possible with the process of monetizing our digital imaging patent portfolio," Timothy Lynch, Kodak's Chief Intellectual Property Officer said.

The company's financial adviser, Lazard, has marketed these assets over the past 12 months, and 20 parties have signed confidentiality agreements to date, the company revealed in a statement.

Kodak, which invented the handheld camera and the digital camera, filed for bankruptcy protection on January 19.

via Yahoo! Finance

Also see: Kodak Posts $114 Million Loss (May 2008) 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Soft drinks are not the major contributor to childhood obesity, say researchers

Consumption of soft drinks and other sweetened beverages is not a major contributor to the rising levels of childhood obesity, according to Canadian research that assesses consumption and risk in over 10,000 children and youths.

The study published in Applied Physiology, Nutrition, and Metabolism examines the relationship between beverage intake patterns of Canadian children and their risk for obesity. Led by Susan Whiting of the University of Saskatchewan, Canada, the researchers revealed that sweetened beverage intake is not a risk factor for childhood obesity in most agree groups, noting that intake seems to be a risk factor only in boys aged 6-11.

Whiting and her colleagues revealed that whilst many children and youths consume soft drinks and other sweetened beverages such as fruit punch and lemonade almost all groups are not at any higher risk for obesity than their peers who drink healthier beverages.

"We found sweetened drinks to be dominant beverages during childhood, but saw no consistent association between beverage intake patterns and overweight and obesity," said Whiting.

However, the lead researcher noted that overconsumption of sweetened beverages may put some children at increased risk for overweight and obesity, especially as consumption habits formed early in life and are often maintained into adulthood.

Indeed, boys aged 6-11 years who consumed mostly soft drinks were shown to be at increased risk for overweight and obesity as compared with those who drank a more moderate beverage pattern," she revealed.

Study details

The researchers noted that sweetened beverage intake has risen in past decades. This increase in consumptions has been matched with a rise in prevalence of overweight and obesity among children.

Our objective was to examine the relationship between beverage intake patterns and overweight and obesity among Canadian children.

The research team determined beverage consumption patterns among Canadian children aged between two years old and 18 years old using cluster analysis where socio-demographics, ethnicity, household income, and food security were significantly different across the clusters.

See original here:
Soft drinks are not the major contributor to childhood obesity, say researchers

Herbalife Becomes Nutrition Sponsor of Team SpiderTech Powered by C10

LOS ANGELES--(BUSINESS WIRE)--

Herbalife Ltd. (HLF) and UCI Professional Cycling Team SpiderTech powered by C10 announced a one year sponsorship agreement making Herbalife the teams Official Nutrition partner.

The riders will be fueled with the new Herbalife24 sports performance line, which includes Formula 1 Sport, Hydrate, Prepare, Prolong, Rebuild Endurance, Rebuild Strength, and Restore.

SpiderTech will compete in the upcoming USA Pro Cycling Challenge in Colorado, as well as having raced in the Amgen Tour of California, two of the biggest cycling stage races in the U.S. In addition, SpiderTech has 100 racing days planned across Europe. With a full-range of sports nutrition products, Team SpiderTech riders will have an optimal pre-race meal, hydration, on-the-bike fuel, and multiple recovery options with Herbalife24. Riders have absolute confidence in the products since every batch of product is certified and tested by BSCG (Banned Substances Control Group, http://www.bscg.org) for illegal performance-enhancing substances.

Herbalife had a deep understanding of athletes nutritional needs when formulating these products, says Steve Bauer, Director Sportif, and Olympic medalist who wore the famed Maillot Jaune (Yellow Jersey) in the Tour de France in 1988 and 1990. The product diversity suits all of our riders needs. Team SpiderTech also hails the fact that the Herbalife24 products do not contain any artificial colors, flavors or sweeteners. Its something a lot of our riders have been advocates for, says Ian McLagan, team manager. In addition to the Herbalife24 line, Herbalife offers a wide array of other supplements including heart health products ranging from omega-3 fish oils to joint health support.

SpiderTech powered by C10 team soigneur comments that the riders love the recovery products, and on cold days, we even serve them warm, something they really look forward to. Rider Guillaume Boivin, who finished 7th at Amgen ToC stage 4, said, Herbalife24 Prolong really helped me have good sensations at the end of the stage. I had good feelings in my legs, and I was able to smash the hammer down in the sprint.

About Herbalife

Herbalife Ltd. (HLF) is a global nutrition company that sells weight-management, nutrition, and personal care products intended to support a healthy lifestyle. Herbalife products are sold in 81 countries through a network of independent distributors. The company supports the Herbalife Family Foundation and its Casa Herbalife program to help bring good nutrition to children. Herbalife's website contains a significant amount of information about Herbalife, including financial and other information for investors at http://ir.Herbalife.com. The company encourages investors to visit its website from time to time, as information is updated and new information is posted.

Follow this link:
Herbalife Becomes Nutrition Sponsor of Team SpiderTech Powered by C10

Mead Johnson Nutrition Announces Steve Golsby’s Intent to Retire as President and CEO in 2013

GLENVIEW, Ill.--(BUSINESS WIRE)--

Mead Johnson Nutrition Company (MJN) announced today that its President and Chief Executive Officer, Steve Golsby, notified the Board of Directors of his intent to retire by the 2013 annual meeting of stockholders. Mr. Golsby informed the Board of his intentions at the Companys Board meeting and pledged his commitment to support the succession plan in the months ahead.

Subsequently, the Board of Directors unanimously selected Kasper Jakobsen, currently Executive Vice President and Chief Operating Officer of Mead Johnson Nutrition, as CEO-elect and appointed him to the MJN Board of Directors effective immediately. Mr. Jakobsen is expected to succeed Mr. Golsby as Mead Johnson Nutrition President and CEO upon Mr. Golsbys retirement. Kasper Jakobsen will continue in his role as Chief Operating Officer, and the current senior leadership structure and reporting relationships will remain in effect.

Chairman of the Board Jim Cornelius stated that, Steve has been an extraordinary leader of the Mead Johnson Nutrition team since the Companys initial public offering (IPO) on the New York Stock Exchange in February 2009, and for many years prior to that, while MJN was a wholly owned subsidiary of Bristol-Myers Squibb. The Board is fully supportive of Mr. Golsby continuing to serve as a director on the MJN Board following his retirement. The Board maintains robust succession plans at all senior levels of the organization contemplating such events. As Steves replacement, Kasper Jakobsen has the confidence of the full Board, reflecting his experience as a 14-year veteran of Mead Johnson, including operational leadership responsibility for the businesses in Asia, North America and Latin America prior to becoming Executive Vice President and Chief Operating Officer earlier this year.

Commenting on his planned retirement, Mr. Golsby thanked the Board for the strong support and insightful guidance it has given him during his tenure as CEO, saying, I feel privileged to have led Mead Johnson for over eight years and to have had the opportunity to manage its transformation into a high-performing public company and a global leader in its category. I know I will be leaving the Company in good hands, with an outstanding Board and talented global management team who can build upon the success we have achieved to date, and I look forward to having the opportunity to serve on the Mead Johnson Board following my retirement as CEO.

About Mead Johnson

Mead Johnson, a global leader in pediatric nutrition, develops, manufactures, markets and distributes more than 70 products in over 50 markets worldwide. The company's mission is to nourish the world's children for the best start in life. The Mead Johnson name has been associated with science-based pediatric nutrition products for over 100 years. The company's "Enfa" family of brands, including Enfamil(R) infant formula, is the world's leading brand franchise in pediatric nutrition.

For more information on the company, go to meadjohnson.com.

More here:
Mead Johnson Nutrition Announces Steve Golsby’s Intent to Retire as President and CEO in 2013

Scientists tie DNA repair to key cell signaling network

Public release date: 15-Jun-2012 [ | E-mail | Share ]

Contact: Jim Kelly jpkelly@utmb.edu 409-772-8791 University of Texas Medical Branch at Galveston

University of Texas Medical Branch at Galveston researchers have found a surprising connection between a key DNA-repair process and a cellular signaling network linked to aging, heart disease, cancer and other chronic conditions. The discovery promises to open up an important new area of research one that could ultimately yield novel treatments for a wide variety of diseases.

"This is a totally new concept it goes against current dogma about the role of DNA repair," said UTMB professor Istvan Boldogh, senior author of a paper on the work now online in the Journal of Biological Chemistry. "We couldn't believe it ourselves, but the data convinced us."

Boldogh and his colleagues came up with the idea of a link between DNA repair and cellular signaling after a close examination of the relationship between DNA damage and cell death produced unexpected results. Conventional DNA-repair dogma holds that a cell's lifespan is determined by the amount of accumulated DNA damage it suffers the overall corruption of genetic information stored in sequences of molecules called bases, which form the "rungs" of the DNA double helix. The cells used in Boldogh's study were especially vulnerable to damage because they lacked a key enzyme that repairs the DNA base guanine. According to dogma, this should have shortened the cells' lives; instead, they actually lived longer than expected. This made Boldogh wonder if another factor was involved in reducing the lifespan of normal cells.

"We proposed the hypothesis that instead of the accumulation of damaged guanine in DNA causing ill effects, what is significant is the release of a DNA-repair byproduct that somehow activates processes that shorten the lifespan of cells," Boldogh said.

The researchers knew just where to look to find this hypothetical repair byproduct. The majority of DNA damage is caused by ubiquitous reactive oxygen species, very chemically active molecules created as byproducts of respiration. When DNA meets reactive oxygen species, one of the most common results is the transformation of the DNA base guanine into a molecule called 8-oxoguanine, which can produce mutations in genes.

To protect the integrity of the genetic code, cells remove 8-oxoguanine from their DNA with a repair enzyme called OGG1. OGG1 does its job by attaching to a damaged base, cutting it free from the DNA molecule, and then releasing it. Boldogh and his collaborators found that their key byproduct was being produced just after this repair process was completed. Analyzing test-tube, cell-culture and mouse experimental data, they realized that immediately after being released by OGG1, 8-oxoguanine reunites with the repair enzyme, attaching at a bonding site different from the one used previously. And the resulting 8-oxoguanine-OGG1 complex, they found, has the ability to activate the powerful Ras signaling pathways, some of the most important biochemical networks in the cell.

"Ras family proteins are involved in almost every cell function: metabolism, activation of genes, growth signals, inflammation signals, apoptosis," Boldogh said. "Because it activates Ras pathways, the release of 8-oxoguanine in DNA base repair could be a master regulator of many very basic processes."

According to Boldogh, learning to control this "master regulator," could result in profound consequences for biomedical science and human health. "The ability to regulate 8-oxoguanine excision may give us the ability to prevent the inflammation that's key to a number of chronic diseases arthritis, atherosclerosis, Alzheimer's and others," he said. "We believe it may even enable us to extend lifespan, or at least healthy lifespan, which would be a very big achievement. Possibilities like that make us believe that this discovery is going to be very significant."

Continue reading here:
Scientists tie DNA repair to key cell signaling network

Posted in DNA

'Tree of Life' symposium at NYBG

Public release date: 15-Jun-2012 [ | E-mail | Share ]

Contact: Stevenson Swanson sswanson@nybg.org 718-817-8512 The New York Botanical Garden

Three leading researchers in evolutionary biology and biodiversity will explore pressing current issues in one of the most important projects in contemporary sciencethe quest to understand the fundamental evolutionary relationships among speciesat the 2012 Lewis B. and Dorothy Cullman Symposium on Wednesday, June 20, at The New York Botanical Garden.

Ever since Charles Darwin sketched a simple tree to illustrate how species are related, scientists have endeavored to construct a "tree of life" that traces the evolutionary ancestry of related species. The advent of fast, reliable DNA sequencing and dramatically increased computing capacity has transformed that endeavor, allowing researchers to discover relationships among species at the molecular level.

The Cullman Symposium, "Assembling the Tree of Life," will cover such subjects as the significance of the tree of life as a scientific endeavor with practical applications, the impact it is having on environmental research and information technology, and its potential to help address a wide array of problems, from climate change to human disease.

Quentin Wheeler, Ph.D., Founding Director of the International Institute for Species Exploration at Arizona State University, will discuss his experiences as the former director of the Division of Environmental Biology at the National Science Foundation, where he was responsible for launching the Assembling the Tree of Life (AToL) program.

Sandra Knapp, Ph.D., Merit Researcher at the Natural History Museum in London, will talk about the importance of understanding the species at the tips of the tree of life, not just its branching patterns, in using tree-of-life information to conserve plant diversity.

Dennis Stevenson, Ph.D., the Botanical Garden's Vice President for Laboratory Research, will draw on his extensive research as a leading evolutionary botanist to show how understanding evolutionary problem solving at the genetic level could help address such current problems as species conservation, climate change, and even human diseases.

From June 16th to June 22nd, the Garden is hosting scientists from around the world who study one of the oldest but often overlooked forms of plant life on Earth--mosses. This group of plants, called bryophytes, was a pivotal step in the evolution of plants from water to land, and their significance in maintaining healthy ecosystems and preserving biodiversity is increasingly recognized.

The weeklong series of scientific presentations and lectures encompasses two separate conferences and the Cullman Symposium, which is held every other year at the Garden to inform a diverse audience, ranging from scientists to the general public, about the latest advances in molecular biology.

Read more:
'Tree of Life' symposium at NYBG

10 foods that can make you look YOUNGER

No anti-aging cream, lotion or medicine can have your skin looking as young as when you consume foods that keep it healthy.

When you have the money, a scalpel and a knife can reverse your natural aging process and have you looking younger, but then it's rather plastic. You can get that genuine radiance from deep within -- a little restructuring of your diet will let the glow stay forever. So here's the list of top 10 foods which will trap your youth for the long term!

1. Nuts

Rich in Vitamin A and omega-3 fatty acids, nuts are a rich source of nutrients vital to your skin. They protect it by forming a fluid, rich membrane in the skin that is moist and flexible. Hence, wrinkles are kept away at bay and the radiance is blemish-free. The fluidity keeps the skin supple and prevents premature aging.

Your pick: Walnuts, pecans, almonds and hazelnuts, chia seeds and flaxseed

LifeMojo is one of the most trusted sources of information about good health and wellness. To those who want to manage their health themselves, LifeMojo provides necessary information, tips, tracking tools and support to help them stay informed and motivated.

Go here to read the rest:
10 foods that can make you look YOUNGER

Osiris Receives Second Approval for Stem Cell Drug

More Topics: Choose a Sector Accounting Firms Advertising/Media/Communications Capital CEO/Board General Business Health/Biotech Internet/Technology Investment Firms Law Firms Mergers & Acquisitions Money Managers People Private Companies Public Companies Venture Capital

Posted June 14, 2012

COLUMBIA, Md. --Osiris Therapeutics, Inc.(NASDAQ: OSIR) has received consent from New Zealand to market its first-in-class stem cell therapy Prochymal (remestemcel-L), for the treatment of acute graft-vs-host disease (GvHD) in children. New Zealand joins Canada, which last month became the world's first internationally recognized regulatory authority to grant approval to a stem cell drug. Prochymal is also the first therapy approved for GvHD - a devastating complication of bone marrow transplantation that kills up to 80 percent of children affected, many within just weeks of diagnosis.

"With each of our approvals it becomes clearer that the time for life-saving stem cell therapies in the practice of medicine has arrived, and we are humbled to have a leading role," saidC. Randal Mills, Ph.D., President and Chief Executive Officer of Osiris. "I would like to thank the professionals at Medsafe for their thoughtful and expeditious review of this complex application. I would also like to thank the team at Osiris that continues to do an outstanding job of making Prochymal available to children around the world suffering from the devastating effects of GvHD."

Osiris submitted a New Medicine Application to Medsafe (New Zealand's medical regulatory agency) in May of 2011, and was granted Priority Review in June of 2011. Priority review provides expedited review for new drugs which offer a significant clinical advantage over current treatment options. Prochymal was granted provisional consent under Section 23 of the Medicines Act 1981.

"The incidence of GvHD is likely to rise as the demographic profile of our transplant population evolves," saidHans Klingemann,M.D., Ph.D., a Professor of Medicine and the Director of the Bone Marrow & Hematopoietic Stem Cell Transplant Program at Tufts University School of Medicine. "Effective strategies to manage the often lethal consequences of GvHD reduce the overall risk to transplantation and provide the transplant physician with better options when approaching their most difficult cases."

Clinical trials have shown that Prochymal is able to induce an objective, clinically meaningful response in 61-64 percent of children with GvHD that is otherwise refractory to treatment. Furthermore, treatment response with Prochymal resulted in a statistically significant improvement in survival.

"As a mother who watched my son Christian suffer and die from the horrifying effects of GvHD, while waiting for the regulatory approvals necessary to allow him access to Prochymal, words cannot express how happy I am that significant progress is finally being made," saidSandy Barker,President and Co-founder of the Gold Rush Cure Foundation. "We are proud to stand side-by-side with Osiris in this historic battle for our children around the world. Our motto is 'not one more child, not one more family' and when it comes to GvHD mortality, zero is the only acceptable number."

Prochymal is now approved in Canada and New Zealand, and is currently available in seven other countries including the United States under an Expanded Access Program (EAP). It is expected that Prochymal will be commercially available in New Zealand later this year.

Osiris Therapeutics, Inc. is a stem cell company, having developed the world's first approved stem cell drug, Prochymal. The company is focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets. Osiris has developed an extensive intellectual property portfolio to protect the company's technology, including 48 U.S. and 144 foreign issued patents.

Original post:
Osiris Receives Second Approval for Stem Cell Drug

Mead Johnson to Present at the 9th Annual Deutsche Bank Global Consumer Conference

GLENVIEW, Ill.--(BUSINESS WIRE)--

Mead Johnson Nutrition Company (MJN) announced today that it will present at the 9th Annual Deutsche Bank Global Consumer Conference in Paris, France, on June 19, 2012. The presentation by Stephen W. Golsby, president and CEO, and Kathy A. MacDonald, vice president, Investor Relations, will begin at 11:15 a.m. CEST and will be available by webcast.

The webcast will be broadcast over the Internet at meadjohnson.com. To listen to the webcast, visit the website at least 15 minutes before the webcast and click on the Investors tab. A webcast link will appear on Latest News and also Events and Presentations. A replay of the webcast will be available one hour after the presentation through midnight CDT Tuesday, July 17, 2012 at meadjohnson.com.

About Mead Johnson

Mead Johnson, a global leader in pediatric nutrition, develops, manufactures, markets and distributes more than 70 products in over 50 countries worldwide. The company's mission is to nourish the worlds children for the best start in life. The Mead Johnson name has been associated with science-based pediatric nutrition products for over 100 years. The company's "Enfa" family of brands, including Enfamil infant formula, is the world's leading brand franchise in pediatric nutrition. For more information, go to http://www.meadjohnson.com.

Continued here:
Mead Johnson to Present at the 9th Annual Deutsche Bank Global Consumer Conference

Crowdfunding Nutrition: Using Kickstarter to Make Kids Healthier

Can the popular startup make a dent in nutrition education? One school finds it more difficult than expected.

Kristy McCarron/Kickstarter

Childhood nutrition and anti-obesity campaigns are a hot topic these days. Gardens and cooking classes are in demand in schools around the country.

But how much would you, personally, be willing to shell out of pocket to help our nation's kids eat healthier? In a time of tight purse strings, several schools are asking that question with the help of the popular crowd-funding site, Kickstarter.

"My name is Kristy McCarron, and this is where I spend my day off," a young woman's voice tells us in the intro video of one Kickstarter campaign. She's referring to a classroom at Walker Jones elementary school in Washington, D.C., where she teaches kids about food -- where it comes from, why it's good for them, and how to cook it, too.

McCarron is now trying to raise $25,000 to help build a "food lab" kitchen at the school, which she would run as a full-time teacher.

While many of us may think of Kickstarter as a place where tech-savvy 20-somethings raise money to make the newest iPhone accessory, McCarron says it was a perfect fit for her school, too.

"I kind of just took a big leap of faith and quit my job and started this fundraising pitch," she says, confessing that she hadn't even heard of Kickstarter until a friend turned her onto it for this project.

McCarron has spent the past 8 months volunteering as a part-time nutrition instructor at Walker Jones, which is a historically African American, title-one high poverty school where 100 percent of the students receive free breakfast, lunch, and dinner. She worked nights as a chef at Nora, a well-known, upscale organic restaurant in downtown D.C.

A lot of excitement has surrounded her classes, from kids and parents alike, she says, though she had to get creative with the classes for lack of equipment.

View original post here:
Crowdfunding Nutrition: Using Kickstarter to Make Kids Healthier

DNA focus for Dechaine trial

1:00 AM

By Ann S. Kim akim@mainetoday.com Staff Writer

PORTLAND -- Expert witnesses who testified Thursday in Dennis Dechaine's hearing on a new trial offered contrasting views on whether the DNA evidence at issue is a result of contamination.

Three DNA experts, with doctorates in genetics and extensive backgrounds in forensic science, testified about the partial DNA profile that is at the center of the multi-day hearing. Dechaine's lawyer, Steve Peterson, is trying to convince a judge that the jurors would not have convicted Dechaine of the 1988 murder and kidnapping of 12-year-old Sarah Cherry had they known about the DNA from an unknown male on the girl's left thumbnail.

Two witnesses for the state testified that the autopsy conditions described to them posed a high risk for DNA contamination. At the time, DNA technology was new and lacked the kinds of safeguards that are used today.

In 1988, the State Medical Examiner's Office did autopsies in the morgue of the Kennebec Valley Medical Center in Augusta. Earlier testimony indicated that instruments were kept in a metal tool box with towel-lined drawers. Instruments were sometimes rinsed and sometimes simply put back into the drawers. The towels got soiled with blood over time and were changed after several months.

"That scenario that you described would really be a textbook recipe for the potential for contamination for many, many steps along the way," Frederick Bieber said after the conditions were recounted by Deputy Attorney General William Stokes.

Bieber, who holds positions at Harvard Medical School and Brigham and Women's Hospital, said he has been at autopsies done under similar conditions, and dozens of people would handle instruments.

It probably wasn't until the early 1990s that precautions to prevent DNA cross-contamination became widespread in autopsy rooms, he said. Before then, it was common for autopsies to be done with bare hands. The first precautions were not related to DNA, but to guard against the transmission of infections like HIV or to protect cells that would be cultured.

Carll Ladd, supervisor of the DNA section of Connecticut's forensic lab, agreed that the conditions at the time of Sarah Cherry's autopsy would have been "ideal" for contamination.

See original here:
DNA focus for Dechaine trial

Posted in DNA

DNA contamination focus of testimonyat Dechaine hearing

1:00 AM

BY ANN S. KIM

PORTLAND -- Expert witnesses who testified Thursday in Dennis Dechaine's hearing on a new trial offered contrasting views on whether the DNA evidence at issue is a result of contamination.

Three DNA experts, with doctorates in genetics and extensive backgrounds in forensic science, testified about the partial DNA profile that is at the center of the multi-day hearing. Dechaine's lawyer, Steve Peterson, is trying to convince a judge that the jurors would not have convicted Dechaine of the 1988 murder and kidnapping of 12-year-old Sarah Cherry had they known about the DNA from an unknown male on the girl's left thumbnail.

Two witnesses for the state testified that the autopsy conditions described to them posed a high risk for DNA contamination. At the time, DNA technology was new and lacked the kinds of safeguards that are used today.

In 1988, the State Medical Examiner's Office did autopsies in the morgue of the Kennebec Valley Medical Center in Augusta. Earlier testimony indicated that instruments were kept in a metal tool box with towel-lined drawers. Instruments were sometimes rinsed and sometimes simply put back into the drawers. The towels got soiled with blood over time and were changed after several months.

"That scenario that you described would really be a textbook recipe for the potential for contamination for many, many steps along the way," Frederick Bieber said after the conditions were recounted by Deputy Attorney General William Stokes.

Bieber, who holds positions at Harvard Medical School and Brigham and Women's Hospital, said he has been at autopsies done under similar conditions, and dozens of people would handle instruments.

It probably wasn't until the early 1990s that precautions to prevent DNA cross-contamination became widespread in autopsy rooms, he said. Before then, it was common for autopsies to be done with bare hands. The first precautions were not related to DNA, but to guard against the transmission of infections like HIV or to protect cells that would be cultured.

Carll Ladd, supervisor of the DNA section of Connecticut's forensic lab, agreed that the conditions at the time of Sarah Cherry's autopsy would have been "ideal" for contamination.

See the original post here:
DNA contamination focus of testimonyat Dechaine hearing

Posted in DNA

DNA test boosts Beaman's innocence claim

BLOOMINGTON New DNA test results shake up the list of possible suspects in the 1993 murder of Jennifer Lockmiller and strengthen Alan Beamans claim of innocence.

Recently tested evidence contained no DNA from Beaman, who spent more than a dozen years in prison before a court ordered him released, or from three other men considered suspects in the death of the Decatur woman. It did, however, contain DNA from two unknown males.

Documents submitted Thursday to the Illinois Prisoner Review Board by Beamans lawyers contained the results of tests a Missouri lab did on a vaginal swab taken from Lockmiller.

Beaman, now 39, was released in 2008, following the reversal of his murder conviction by the Illinois Supreme Court in an opinion that called the evidence in his 1995 jury trial tenuous.

McLean County prosecutors opted to dismiss the murder charges against Beaman but have maintained that authorities consider Lockmillers death an open case. Beaman and Lockmiller had a rocky dating relationship that ended shortly before she was found strangled and stabbed in her Normal apartment.

Assistant States Attorney Pablo Eves said Thursday that his office has received the results, which are being reviewed.

The significance of the new evidence cannot be overstated, said Beaman lawyers Karen Daniel and Jeff Urdangen in their supplemental report to the clemency board considering recommending a pardon to Gov. Pat Quinn.

Crime scene evidence indicating that Lockmiller had been sexually assaulted combined with the DNA report very strongly suggests that at least one, if not both, of the contributors of the semen raped and killed her, said the lawyers.

The DNA report also demonstrates that the prosecutions theory of the case at Alan Beamans trial was utterly false, said the lawyers with the Center on Wrongful Convictions in Chicago.

The recent round of DNA testing was completed as part of a certificate of innocence petition filed by Beaman in 2009. The McLean County States Attorneys Office has opposed the certificate, which, if granted, would qualify Beaman to receive $170,000 from the state as compensation for the 13 years he served of a 50-year sentence.

More:
DNA test boosts Beaman's innocence claim

Posted in DNA

Special Alan Turing issue Fundamenta Informaticae published

Public release date: 14-Jun-2012 [ | E-mail | Share ]

Contact: A. Engelen a.engelen@iospress.nl 31-206-883-355 IOS Press

The journal Fundamenta Informaticae honours Alan Turing with a Special Issue: Watching the Daisies Grow: from Biology to Biomathematics and Bioinformatics.

In 1951 Alan Turing wrote a paper entitled The Chemical Basis of Morphogenesis in which he developed the reactiondiffusion theory, which became one of the basic models of theoretical biology and is also considered a foundation of chaos theory.

The story started much earlier, in spring 1923, as documented by his mother in a caricature called Hockey or Watching the Daisies Grow. Crucial motif in the drawing is that, while most players are engaged by the game, Turing is investigating a flower emerging just off the field.

In his Outline of the Development of a Daisy, Turing writes: "At a certain point in the development of the daisy the anatomical changes begin. From this point, as has been mentioned, it becomes hopelessly impracticable to follow the process mathematically."

Guest-editors Anna Gambin and Anna Marciniak-Czochra: "In this special issue, we present a selection of papers commemorating Alan Turing and arguing that he should be also considered the co-founder of biomathematics and bioinformatics. His late works were inspired by curiosity about the role of mathematics in natural phenomena. Turing's ideas on diffusion-driven instability leading to a formation of stable spatial structures provided mathematical explanations of symmetry break and de novo pattern formation during development, and the shapes of animal coat markings. They also led to the prediction of oscillating chemical reactions, the behavior which were first observed only about 10 years after Turing's death. In this volume, various applications of mathematical theories inspired by Turing's work to natural phenomena are considered."

###

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Continued here:
Special Alan Turing issue Fundamenta Informaticae published

ReNeuron Group plc – PISCES Trial Interim Data

ReNeuron Group (Berlin: RQE.BE - news) plc

(the "Company")

Interim data from clinical trial of ReNeuron's stem cell therapy for stroke to be presented at leading scientific conference

Data show no safety concerns and evidence of sustained reductions in neurological impairment and spasticity

Guildford, UK, 14 June 2012: ReNeuron Group plc (the "Company") (LSE: RENE.L) is pleased to announce the presentation of interim data from the PISCES (Pilot Investigation of Stem Cells in Stroke) clinical trial of its ReN001 stem cell therapy for disabled stroke patients. In this open label, dose-ranging Phase I safety study, ReNeuron's ReN001 stem cell therapy is being administered in ascending doses to a total of 12 stroke patients who have been left disabled by an ischaemic stroke, the most common form of the condition.

The primary aim of the study is to test the safety and tolerability of the treatment in ascending doses of the ReN001 cells, in patients with moderate to severe functional neurological impairments resulting from their stroke. The secondary aim of the study is to evaluate efficacy measures for the design of future clinical trials with ReN001, including imaging measures as well as a number of tests of sensory, motor and cognitive functions.

To date, six patients have been treated in the PISCES stroke study, representing the first two of four dose cohorts. The interim data being presented are from the first five patients treated, at 2 x 12 month, 1 x six month and 2 x three month follow-up points.

No cell-related adverse events or adverse immune-related responses were reported in any of the patients treated to date. A number of the patients experienced minor procedure-related adverse events such as asymptomatic bleeds or superficial scalp infections at the implantation wound site.

Reductions in neurological impairment and spasticity were observed in all five patients compared with their stable pre-treatment baseline performance and these improvements were sustained in longer term follow-up.

Neurological deficits were measured using the National Institutes of Health Stroke Scale (NIHSS), a higher score representing a worse deficit. Patients are required to have a NIHSS score of at least 6 to participate in the study. The pre-treatment median score for the first five patients was 8 (range 6 to 10) and the three month post-treatment median score was 4 (range 3 to 9).

Go here to read the rest:
ReNeuron Group plc - PISCES Trial Interim Data